Article Text

Download PDFPDF

LBP2 Development and validation of a patient-centered autoevaluation questionnaire in systemic lupus erythematosus: LUPIN
  1. Marc Scherlinger1,
  2. Jean François Kleinmann2,
  3. Antonin Folliasson3,
  4. Marianne Riviere4,
  5. Raphaëlle Rybak4,
  6. Sabine Malivoir5,
  7. Jean-François Viallard6,
  8. Frédéric Renou7,
  9. Estibaliz Lazaro8,
  10. Christophe Richez8,
  11. Pascal Roblot9,
  12. Mathieu Puyade10,
  13. Clara Baverez11,
  14. Arnaud Hot12,
  15. Christophe Deligny13,
  16. Nicolas Baillet14,
  17. Daniel Wendling15,
  18. Julien Campagne16,
  19. Christian Agard17,
  20. Roland Jaussaud18,
  21. Thomas Moulinet19,
  22. Denis Wahl20,
  23. Gilles Blaison21,
  24. Elisabeth Diot22,
  25. Nicole Ferreira-Maldent23,
  26. Isabelle Marie24,
  27. Nicolas Girszyn24,
  28. Laurent Perard25,
  29. Marc André26,
  30. Pauline Orquevaux27,
  31. Amelie Servettaz28,
  32. François Chasset29,
  33. Baptiste Hervier30,
  34. Thierry Martin31,
  35. Cécile Fermont32,
  36. Emmanuelle David33,
  37. Loic Raffray34,
  38. Ludovic Trefond35,
  39. Perrine Smets35,
  40. Julie Lescanff36,
  41. Jacques-Eric Gottenberg37,
  42. Xavier Mariette38,
  43. Zahir Amoura5 and
  44. Jean Sibilia37
  1. 1Strasbourg University Hospital – National reference center for autoimmune disease, Rheumatology, Strasbourg, France
  2. 2Les hôpitaux Universitaires de Strasbourg, Centre National de Référence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Strasbourg, France
  3. 3Hometrix Health, Paris, France
  4. 4Association Française du Lupus et autres Maladies Autoimmunes (AFL+), Metz, France
  5. 5APHP Pitié Salpêtrière, Centre National de Référence des Maladies Autoimmunes et Autoinflammatoires Rares, Paris, France
  6. 6CHU de Bordeaux, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Bordeaux, France
  7. 7CHU de Saint Denis, Médecine interne, Saint Denis, Reunion Island
  8. 8CHU Bordeaux, Centre National de Référence Maladies Autoimmunes Systémiques Rares, Bordeaux, France
  9. 9CHU la Milétrie, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Poitiers, France
  10. 10CHU la Milétrie, Poitiers, France
  11. 11Hôpital Edouard Herriot – HCL, Lyon, France
  12. 12Hôpital Edouard Herriot – HCL, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Lyon, France
  13. 13CHU de Martinique, Centre National de Référence des Maladies Autoimmunes et Autoinflammatoires Rares, Fort de France, Martinique
  14. 14CH Basse Terre, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Basse Terre, Guadeloupe
  15. 15CHU Besançon, Besançon, France
  16. 16Hôpital Robert Schuman, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Vantoux, France
  17. 17CHU Nantes, Centre National de Référence des Maladies Autoimmunes et Autoinflammatoires Rares, Nantes, France
  18. 18Hôpitaux de Brabois, Vandoeuvre-les-Nancy, France
  19. 19Hôpitaux de Brabois, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Vandoeuvre-les-Nancy, France
  20. 20Hôpitaux de Brabois, Centre National de Référence des Maladies Autoimmunes et Autoinflammatoires Rares, Nancy, France
  21. 21Hôpital Louis Pasteur, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Colmar, France
  22. 22CHRU de Tours – Hôpital Bretonneau, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Tours, France
  23. 23CHRU Bretonneau – Tours, Tours, France
  24. 24CHU de Rouen, Rouen, France
  25. 25Saint Joseph, Lyon, France
  26. 26Hôpital Gabriel Montpied, Centre National de Référence des Maladies Autoimmunes et Autoinflammatoires Rares, Clermont-Ferrand, France
  27. 27CHU de Reims, Reims, France
  28. 28CHU de Reims, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Reims, France
  29. 29Hôpital Tenon, Sorbonne Université, AP-HP, Centre National de Référence des Maladies Autoimmunes et Autoinflammatoires Rares, Paris, France
  30. 30Hôpital Saint- Louis APHP, Centre de Compétence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Paris, France
  31. 31Nouvel Hôpital Civil, Centre National de Référence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Strasbourg, France
  32. 32CH de Valence, Valence, France
  33. 33Hôpital de la Croix Rousse – HCL, Lyon, France
  34. 34CHU Réunion site Nord, Saint Denis, France
  35. 35CHU Clermont Ferrand, Clermont Ferrand, France
  36. 36CH Villefranche sur Saône, Villefranche sur Saône, France
  37. 37Les Hôpitaux Universitaires de Strasbourg, Centre National de Référence Maladies Autoimmunes et Autoinflammatoires Systémiques Rares, Strasbourg, France
  38. 38APHP Hôpital Bicêtre, Centre National de Référence des Maladies Autoimmunes et Autoinflammatoires Rares, Le Kremlin-Bicêtre, France

Abstract

Objectives To develop and evaluate a self-administered questionnaire (LUPIN) to assess SLE disease activity and lupus-relevant PROs.

Methods Patient representatives from a nationwide lupus association (AFL+) and lupus experts developed a self- administered questionnaire which included several domains of SLE perceived activity (figure 1) and the SF-36 quality of life questionnaire. Prior to a medical consultation, the patient filled the questionnaire which was sealed. Subsequently, the physician evaluated the patient (blindly of the patient responses) and filled patient characteristics, a physician global assessment (PhGA) and a SLEDAI-2K. The questionnaires were distributed to 31 centers of metropolitan France and overseas territories. Correlations between patient response in individual domains and physician assessment were evaluated using Spearman’s regression and p-values were adjusted for multiple testing using the Bonferroni method.

Results 325 questionnaires were analyzed at the time of the submission. The mean age was 44 (±14.4) years and 85,2% were women. The mean duration of disease was 12.7 (±9.42) years. Most patients had history of articular and cutaneous involvements (86.6% and 72.6%, respectively) and 34.4% of lupus nephritis. The mean SLEDAI was 3 (±3.70) and 67 (20.6%) patients had a clinical SLEDAI ≥ 4. The PhGA correlated moderately with the cSLEDAI (r = 0.52). As expected, there was a weak albeit statistically significant correlation between components of the LUPIN questionnaire and the SLEDAI/cSLEDAI and PhGA (r < 0.25 for all; figure 2). However, there were very good correlations between several components of the LUPIN questionnaire and several domains of the SF-36 (r = -0.68 for pain evaluation; r = -0.65 for physical activity evaluation; r = -0.60 for fatigue evaluation; p < 0.0001 for all).

Abstract LBP2 Figure 1

The LUPIN questionnaire (paper or electronic form)

Abstract LBP2 Figure 2

Spearman’s correlation matrix between components of the LUPIN questionnaire, the SF-36 questionnaire and the physician’s assessment of disease activity. Each value corresponds to the spearman r value, in bold when there is a statistically significant correlation after adjusting p-value for multiple testing using the Bonferroni method.

Conclusion Several components of the LUPIN questionnaires have significant correlation with domains of the SF-36 quality of life questionnaire making LUPIN a patient-friendly tool to evaluate PROs now that it has been implemented on smartphones. As expected in a cross-sectional study, there were only weak correlations between domains of the LUPIN questionnaire and physician-assessed disease activity. However, the changes in LUPIN scores assessed prospectively may be more sensitive to detect disease activity fluctuation, which is currently evaluated in a follow-up study.

Acknowledgments All patients and physicians who participated in the study. The AFL+ patient association represented by her president Marianne Riviere.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ .

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.